- Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumorsWang, J.; Zhao, J.; Zhong, J.; Li, X.; Fang, J.; Yu, Y.; Li, X.; Fang, X.; Chang, J.; Liu, Z.; Zhao, Y.; Song, Q.; Bai, C.; Wang-Gillam, A.; Ding, Y.; Rao, Z.; Bi, C.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.被引 1
- The distribution of genetic mutations correlated with resistance to KRASG12C inhibitors in Chinese patients with lung cancer.Lin, Shengcheng; Ma, Kai; Xu, Yafei; Liu, Xinyi; Huang, Xiaochun; Huang, MengliAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- Efficacy of anlotinib in posterior line treatment of locally advanced and metastatic NSCLC with KRAS mutationLi, X.ESMO Asia Congress, Singapore, SINGAPORE, 2022-12-02 To 2022-12-04.
会议论文
Efficacy and safety of IBI351 (GFH925), a selective KRASG12C inhibitor, monotherapy in patients (pts) with advanced nonsmall cell lung cancer (NSCLC): Initial results from a registrational phase II study
21阅读
